Please check back later to see all of our exciting changes. ...

NEW ORLEANS, Jan. 15, 2025 (GLOBE NEWSWIRE) -- ClaimsFiler, a FREE shareholder information service, reminds investors that they have until March 14, 2025 to file lead plaintiff applications in a securities class action lawsuit against Pacira BioSciences, Inc. (the “Company”) (NasdaqGS: PCRX), if they purchased the Company’s securities between August 2, 2023 and August 8, 2024, inclusive (the “Class Period”). This action is pending in the United States District Court for the District of New Jersey. Get Help ...

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $75,000 In Pacira To Contact Him Directly To Discuss Their OptionsIf you suffered losses exceeding $75,000 in Pacira between August 2, 2023 and August 8, 2024 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).[You may also click here for additional information]NEW YORK, Jan. 15, 2025 /PRNewswire/ -- ...

NEW YORK, Jan. 15, 2025 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, announces that a shareholder filed a class action lawsuit on behalf of purchasers of securities of Pacira BioSciences, Inc. (NASDAQ: PCRX) between August 2, 2023 and August 8, 2024. A lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than March 14, 2025.So what: If you purchased Pacira securities during the Class Period, you may be entitled to compensation without ...

Class Action Lawsuit Against Pacira BioSciences - A class action lawsuit has been filed on behalf of individuals and entities that purchased or acquired Pacira BioSciences securities between August 2, 2023, and August 8, 2024 [1] - Pacira BioSciences is a pharmaceutical company focused on non-opioid pain management and regenerative health solutions [1] Allegations of Misrepresentation - The lawsuit alleges that Pacira BioSciences failed to disclose the lack of sufficient patent protection for its key product, Exparel [2] - Exparel, a bupivacaine liposome injectable suspension, accounts for approximately 80% of Pacira's revenue [3] - The company allegedly created a false impression that it had strong patent protections for Exparel, despite knowing that the '495 patent was not as protective as claimed [2] - On June 6, 2023, a New Jersey District Court ruled against Pacira in a patent infringement case against eVenus Pharmaceuticals related to Exparel [2] Impact on Stock Price - When Pacira announced the loss of the second lawsuit against eVenus on August 9, 2024, its stock price dropped from $22.36 per share to $11.70 per share, a decline of over 47% in a single day [3] Legal Proceedings and Shareholder Participation - Shareholders who wish to serve as lead plaintiff in the class action must submit their application to the court by March 14, 2025 [4] - Shareholders can choose to remain absent class members and still be eligible for recovery without participating in the case [4] - Robbins LLP, the law firm handling the case, operates on a contingency fee basis, meaning shareholders pay no fees or expenses [5]

Lawsuit Allegations - A shareholder class action lawsuit has been filed against Pacira BioSciences, Inc alleging that the company created a false impression regarding the sufficiency of patent protections on Exparel, impacting its marketing, production, and sales [1] - The lawsuit claims that Pacira was aware that the '495 patent was not as protective as publicly stated by the company [1] Legal Action Details - Shareholders who purchased Pacira shares between August 2, 2023, and August 8, 2024, and suffered significant losses are encouraged to contact Corey D Holzer, Esq for legal rights discussion [2] - The deadline to request the court to be appointed lead plaintiff in the case is March 14, 2025 [3] Law Firm Information - Holzer & Holzer, LLC, a top-rated securities litigation law firm, specializes in representing shareholders and investors in litigation, including class action and derivative cases [3] - Since its founding in 2000, the firm has recovered hundreds of millions of dollars for shareholders affected by fraud and corporate misconduct [3]

NEW YORK, Jan. 13, 2025 (GLOBE NEWSWIRE) -- The following statement is being issued by Levi & Korsinsky, LLP: To: All persons or entities who purchased or otherwise acquired securities of Pacira BioSciences, Inc. (“Pacira” or the “Company”) (NASDAQ: PCRX) between August 2, 2023 to August 8, 2024, both dates inclusive. You are hereby notified that the class action lawsuit Leandro Alvarez v. Pacira BioSciences, Inc., et al. (Case No. 2:25-cv-00322) has been commenced in the United States District Court for th ...

Shares of Pacira BioSciences (PCRX) gained 11.1% on Friday after the company shared better-than-expected preliminary fourth-quarter 2024 sales figures for its marketed products.Additionally, the company unveiled a five-year growth strategy aimed at accelerating its transformation into an innovative biopharmaceutical company and establishing itself as a leader in musculoskeletal pain and related areas. This has also likely contributed to the stock price rally.PCRX’s Preliminary Q4 2024 ResultsExparel’s net p ...

Earnings and Revenue Expectations - The specialty drugmaker is expected to post quarterly earnings of $0 83 per share, representing a year-over-year change of -6 7% [1] - Revenues are expected to be $178 98 million, down 1 3% from the year-ago quarter [1] - Empirical research shows that trends in earnings estimate revisions are strongly correlated with near-term stock price movements [1] Pacira (PCRX) Stock Performance and Estimates - The consensus EPS estimate for Pacira has been revised 0 6% lower over the last 30 days [2] - Pacira shares ended the last trading session 11 1% higher at $20 64, with a higher-than-average trading volume [3] - The stock had previously experienced a 6 2% loss over the past four weeks [3] - The sudden rise in stock price followed better-than-expected preliminary fourth-quarter 2024 sales figures and the unveiling of a five-year growth strategy [4] Industry and Peer Comparison - Pacira is a member of the Zacks Medical - Biomedical and Genetics industry [2] - Travere Therapeutics (TVTX), another stock in the same industry, finished the last trading session 4 8% lower at $18 09 but has returned 6 1% over the past month [2] - Travere's consensus EPS estimate for the upcoming report has changed -7 6% over the past month to -$0 61, representing a year-over-year change of +47 4% [5] - Travere currently holds a Zacks Rank of 2 (Buy) [5]

Core Viewpoint - Pacira BioSciences, Inc. is focused on transforming into an innovative biopharmaceutical organization with a five-year growth plan aimed at becoming a leader in musculoskeletal pain management, reporting preliminary unaudited revenue of $701.0 million for 2024, up from $675.0 million in 2023 [1][2]. Group 1: Financial Performance - Preliminary unaudited total revenue for 2024 is reported at $701.0 million, an increase of 3.7% from $675.0 million in 2023 [1]. - Fourth quarter net product sales for EXPAREL reached $147.7 million in 2024, compared to $143.9 million in 2023, with volume growth and a price increase partially offset by a shift in vial mix and discounting [8]. - Full-year EXPAREL net product sales totaled $549.0 million in 2024, up from $538.1 million in 2023, driven by a 4% average daily volume growth [8]. Group 2: Growth Strategy - The company aims to achieve five objectives by 2030 under its "5x30" plan, focusing on growth, operational excellence, and addressing unmet patient needs in musculoskeletal pain [2]. - Pacira is committed to expanding its clinical pipeline with five novel programs in development and establishing five partnerships, including pipeline and commercial agreements [7]. Group 3: Product Performance - Fourth quarter ZILRETTA net product sales were $33.1 million in 2024, up from $28.7 million in 2023, while iovera° net product sales increased to $6.5 million from $6.0 million in the same period [8]. - Full-year ZILRETTA net product sales reached $118.1 million in 2024, compared to $111.1 million in 2023, and iovera° net product sales were $22.8 million, up from $19.7 million [8]. Group 4: Market Position - Pacira has treated more than three million patients annually and is experiencing a double-digit compounded annual growth rate in product revenue [7]. - The company is positioned to extend its leadership in non-opioid pain management with a best-in-class commercial portfolio generating significant cash flow [2].